Introduction
Melanoma accounts for approximately 1% of skin cancer cases, but causes a large majority of skin cancer deaths. Immunotherapy is the use of targeted therapy to stimulate patient's own immune system to recognize and destroy cancer cells more effectively.
Recently, former President Jimmy Carter, who had metastatic melanoma to the brain and liver, was treated with the drug pembrolizumab, a type of drug known as an immune checkpoint inhibitor, which blocks a protein called PD-1. The complete remission of Jimmy Carter's melanoma shows the great potential of immunotherapy for melanoma.
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This new type of immunotherapy has harnessed and released the body's own biological weapons to create mass tumor destruction.
In melanoma, tumor-associated immune suppression can lead to defective T-cell mediated antitumor immunity. CD8 cytotoxic T-cells play a critical role in host defense against cancers; however, the presence of antigen-specific CD8 T-cells does not always imply that cancers and/or pathogens are efficiently eliminated in the body. 4 In tumor infiltrating lymphocytes (TILs), markers including CD8, CD103, PD-1 and FOXP3 are broadly expressed and have shown a wide range of immunoregulatory and important roles in T-cell activation and in T-cell regulatory and in programmed cell-death checkpoints. [5] [6] [7] [8] [9] Studies have also shown that the high ratios and/or the co-expression of PD-1 + and CD8 + in tumor cells identified poor prognosis; and conversely, the co-expression of CD8 + and CD103 + identified a favorable prognosis. [5] [6] [7] In another study, the authors reported that the majority of TILs, including MART-1 melanoma antigen-specific CD8 T-cells, predominantly expressed PD-1. 
